세계의 파클리탁셀 주사 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Paclitaxel Injection Market - Scope of Report

TMR's report on the global Paclitaxel Injection Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Paclitaxel Injection Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Paclitaxel Injection Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Paclitaxel Injection Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Paclitaxel Injection Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Paclitaxel Injection Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Paclitaxel Injection Market.

The report delves into the competitive landscape of the global Paclitaxel Injection Market. Key players operating in the global Paclitaxel Injection Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Paclitaxel Injection Market profiled in this report.

Key Questions Answered in Global Paclitaxel Injection Market Report:

• What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
• What are the opportunities in the global Paclitaxel Injection Market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Paclitaxel Injection Market - Research Objectives and Research Approach

The comprehensive report on the global Paclitaxel Injection Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Paclitaxel Injection Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Paclitaxel Injection.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Paclitaxel Injection Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Paclitaxel Injection Market Analysis and Forecast, 2017-2031
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Pricing Analysis
• 5.2. Diseases Prevalence & Incidence Rate Globally and with the Key Countries
• 5.3. Covid-19 Pandemic Impact on the Industry

6. Global Paclitaxel Injection Market Analysis and Forecast, by Application

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast, by Application, 2017-2031
  • 6.3.1. Ovarian Carcinoma
  • 6.3.2. Breast Carcinoma
  • 6.3.3. Pancreatic Cancer
  • 6.3.4. Advanced Non-small Cell Lung Carcinoma
  • 6.3.5. Others (AIDS-related Kaposi's sarcoma, etc.)
• 6.4. Market Attractiveness Analysis, by Application

7. Global Paclitaxel Injection Market Analysis and Forecast, by Distribution Channel

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Online Pharmacies
  • 7.3.3. Retail Pharmacies
• 7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Paclitaxel Injection Market Analysis and Forecast, by Region

• 8.1. Key Findings
• 8.2. Market Value Forecast, by Region
  • 8.2.1. North America
  • 8.2.2. Europe
  • 8.2.3. Asia Pacific
  • 8.2.4. Latin America
  • 8.2.5. Middle East & Africa
• 8.3. Market Attractiveness Analysis, by Region

9. North America Paclitaxel Injection Market Analysis and Forecast

• 9.1. Introduction
  • 9.1.1. Key Findings
• 9.2. Market Value Forecast, by Application, 2017-2031
  • 9.2.1. Ovarian Carcinoma
  • 9.2.2. Breast Carcinoma
  • 9.2.3. Pancreatic Cancer
  • 9.2.4. Advanced Non-small Cell Lung Carcinoma
  • 9.2.5. Others (AIDS-related Kaposi's sarcoma, etc.)
• 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Online Pharmacies
  • 9.3.3. Retail Pharmacies
• 9.4. Market Value Forecast, by Country, 2017-2031
  • 9.4.1. U.S.
  • 9.4.2. Canada
• 9.5. Market Attractiveness Analysis
  • 9.5.1. By Application
  • 9.5.2. By Distribution Channel
  • 9.5.3. By Country

10. Europe Paclitaxel Injection Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast, by Application, 2017-2031
  • 10.2.1. Ovarian Carcinoma
  • 10.2.2. Breast Carcinoma
  • 10.2.3. Pancreatic Cancer
  • 10.2.4. Advanced Non-small Cell Lung Carcinoma
  • 10.2.5. Others (AIDS-related Kaposi's sarcoma, etc.)
• 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Online Pharmacies
  • 10.3.3. Retail Pharmacies
• 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 10.4.1. Germany
  • 10.4.2. U.K.
  • 10.4.3. France
  • 10.4.4. Italy
  • 10.4.5. Spain
  • 10.4.6. Rest of Europe
• 10.5. Market Attractiveness Analysis
  • 10.5.1. By Application
  • 10.5.2. By Distribution Channel
  • 10.5.3. By Country/Sub-region

11. Asia Pacific Paclitaxel Injection Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Application, 2017-2031
  • 11.2.1. Ovarian Carcinoma
  • 11.2.2. Breast Carcinoma
  • 11.2.3. Pancreatic Cancer
  • 11.2.4. Advanced Non-small Cell Lung Carcinoma
  • 11.2.5. Others (AIDS-related Kaposi's sarcoma, etc.)
• 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 11.3.1. Hospital Pharmacies
  • 11.3.2. Online Pharmacies
  • 11.3.3. Retail Pharmacies
• 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.4.1. China
  • 11.4.2. Japan
  • 11.4.3. India
  • 11.4.4. Australia & New Zealand
  • 11.4.5. Rest of Asia Pacific
• 11.5. Market Attractiveness Analysis
  • 11.5.1. By Application
  • 11.5.2. By Distribution Channel
  • 11.5.3. By Country/Sub-region

12. Latin America Paclitaxel Injection Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Application, 2017-2031
  • 12.2.1. Ovarian Carcinoma
  • 12.2.2. Breast Carcinoma
  • 12.2.3. Pancreatic Cancer
  • 12.2.4. Advanced Non-small Cell Lung Carcinoma
  • 12.2.5. Others (AIDS-related Kaposi's sarcoma, etc.)
• 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 12.3.1. Hospital Pharmacies
  • 12.3.2. Online Pharmacies
  • 12.3.3. Retail Pharmacies
• 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.4.1. Brazil
  • 12.4.2. Mexico
  • 12.4.3. Rest of Latin America
• 12.5. Market Attractiveness Analysis
  • 12.5.1. By Application
  • 12.5.2. By Distribution Channel
  • 12.5.3. By Country/Sub-region

13. Middle East & Africa Paclitaxel Injection Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Application, 2017-2031
  • 13.2.1. Ovarian Carcinoma
  • 13.2.2. Breast Carcinoma
  • 13.2.3. Pancreatic Cancer
  • 13.2.4. Advanced Non-small Cell Lung Carcinoma
  • 13.2.5. Others (AIDS-related Kaposi's sarcoma, etc.)
• 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 13.3.1. Hospital Pharmacies
  • 13.3.2. Online Pharmacies
  • 13.3.3. Retail Pharmacies
• 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.4.1. GCC Countries
  • 13.4.2. South Africa
  • 13.4.3. Rest of Middle East & Africa
• 13.5. Market Attractiveness Analysis
  • 13.5.1. By Application
  • 13.5.2. By Distribution Channel
  • 13.5.3. By Country/Sub-region

14. Competition Landscape

• 14.1. Market Player - Competition Matrix (by tier and size of companies)
• 14.2. Market Share Analysis, by Company, 2021
• 14.3. Company Profiles
  • 14.3.1. Accord Healthcare Ireland Ltd.
    • 14.3.1.1. Company Overview
    • 14.3.1.2. Financial Overview
    • 14.3.1.3. Product Portfolio
    • 14.3.1.4. Business Strategies
    • 14.3.1.5. Recent Developments
  • 14.3.2. Alembic Pharmaceuticals Limited
    • 14.3.2.1. Company Overview
    • 14.3.2.2. Financial Overview
    • 14.3.2.3. Product Portfolio
    • 14.3.2.4. Business Strategies
    • 14.3.2.5. Recent Developments
  • 14.3.3. American Regent, Inc.
    • 14.3.3.1. Company Overview
    • 14.3.3.2. Financial Overview
    • 14.3.3.3. Product Portfolio
    • 14.3.3.4. Business Strategies
    • 14.3.3.5. Recent Developments
  • 14.3.4. Dash Pharmaceuticals LLC
    • 14.3.4.1. Company Overview
    • 14.3.4.2. Financial Overview
    • 14.3.4.3. Product Portfolio
    • 14.3.4.4. Business Strategies
    • 14.3.4.5. Recent Developments
  • 14.3.5. Dr. Reddy's Laboratories Ltd.
    • 14.3.5.1. Company Overview
    • 14.3.5.2. Financial Overview
    • 14.3.5.3. Product Portfolio
    • 14.3.5.4. Business Strategies
    • 14.3.5.5. Recent Developments
  • 14.3.6. Fresenius Kabi India Pvt. Ltd.
    • 14.3.6.1. Company Overview
    • 14.3.6.2. Financial Overview
    • 14.3.6.3. Product Portfolio
    • 14.3.6.4. Business Strategies
    • 14.3.6.5. Recent Developments
  • 14.3.7. Gland Pharma Limited
    • 14.3.7.1. Company Overview
    • 14.3.7.2. Financial Overview
    • 14.3.7.3. Product Portfolio
    • 14.3.7.4. Business Strategies
    • 14.3.7.5. Recent Developments
  • 14.3.8. Heter
    • 14.3.8.1. Company Overview
    • 14.3.8.2. Financial Overview
    • 14.3.8.3. Product Portfolio
    • 14.3.8.4. Business Strategies
    • 14.3.8.5. Recent Developments
  • 14.3.9. Intas Pharmaceuticals Ltd.
    • 14.3.9.1. Company Overview
    • 14.3.9.2. Financial Overview
    • 14.3.9.3. Product Portfolio
    • 14.3.9.4. Business Strategies
    • 14.3.9.5. Recent Developments
  • 14.3.10. MSN Laboratories
    • 14.3.10.1. Company Overview
    • 14.3.10.2. Financial Overview
    • 14.3.10.3. Product Portfolio
    • 14.3.10.4. Business Strategies
    • 14.3.10.5. Recent Developments
  • 14.3.11. Panacea Biotec
    • 14.3.11.1. Company Overview
    • 14.3.11.2. Financial Overview
    • 14.3.11.3. Product Portfolio
    • 14.3.11.4. Business Strategies
    • 14.3.11.5. Recent Developments
  • 14.3.12. Pfizer, Inc.
    • 14.3.12.1. Company Overview
    • 14.3.12.2. Financial Overview
    • 14.3.12.3. Product Portfolio
    • 14.3.12.4. Business Strategies
    • 14.3.12.5. Recent Developments
  • 14.3.13. Sandoz International GmbH
    • 14.3.13.1. Company Overview
    • 14.3.13.2. Financial Overview
    • 14.3.13.3. Product Portfolio
    • 14.3.13.4. Business Strategies
    • 14.3.13.5. Recent Developments
  • 14.3.14. Teva Pharmaceutical Industries Ltd.
    • 14.3.14.1. Company Overview
    • 14.3.14.2. Financial Overview
    • 14.3.14.3. Product Portfolio
    • 14.3.14.4. Business Strategies
    • 14.3.14.5. Recent Developments
  • 14.3.15. Zydus Group
    • 14.3.15.1. Company Overview
    • 14.3.15.2. Financial Overview
    • 14.3.15.3. Product Portfolio
    • 14.3.15.4. Business Strategies
    • 14.3.15.5. Recent Developments
  • 14.3.16. Apotex Corp.
    • 14.3.16.1. Company Overview
    • 14.3.16.2. Financial Overview
    • 14.3.16.3. Product Portfolio
    • 14.3.16.4. Business Strategies
    • 14.3.16.5. Recent Developments